Coronado's bowel disease treatment fails in mid-stage study
Key points
- Coronado Biosciences Inc said its treatment for Crohn's disease, a type of inflammatory bowel disease, failed the main goal of improving patients' response to the disease in a mid-stage study, sending its shares down 70 percent.
- The treatment, Trichuris suis ova, comprised eggs taken from a pig whipworm.
- Falk Pharma GmbH is conducting a mid-stage study in Europe, testing three doses of TSO in active Crohn's disease.
- Coronado Chief Executive Harlan Weisman said the company would analyze data from its trial, along with the anticipated data from its partner's European study to decide on the treatment's future development.
Coronado Biosciences Inc said its treatment for Crohn's disease, a type of inflammatory bowel disease, failed the main goal of improving patients' response to the disease in a mid-stage study, sending its shares down 70 percent.
The treatment, Trichuris suis ova, comprised eggs taken from a pig whipworm. It is intended to modulate a patient's immune system and prevent it from attacking the body's own tissues and organs.
Coronado's partner Dr. Falk Pharma GmbH is conducting a mid-stage study in Europe, testing three doses of TSO in active Crohn's disease. Data from the study is expected in the fourth quarter, Coronado said.
Coronado Chief Executive Harlan Weisman said the company would analyze data from its trial, along with the anticipated data from its partner's European study to decide on the treatment's future development.
Coronado's trial enrolled 250 patients, dosed with either TSO or placebo once every two weeks, for 12 weeks.
The company said the response rate of patients with moderate-to-severe Crohn's disease taking the treatment was not different from patients taking the placebo as measured on a clinical scale.
Coronado said the treatment was safe and well-tolerated. Adverse events including abdominal pain were balanced between patients taking the treatment and those in the placebo group.
Shares of the company were down at $1.79 in early trading on the Nasdaq. They touched a life-low of $1.73.
###
Reuters
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Digestive Health →NewsPossible drug target found for common bowel disease
The molecular switch that allows people to feel the heat of chilli peppers is a promising new target for drugs against irritable bowel syndrome, British researchers said on Tuesday. They found people with the common and…
11 June 2008
NewsIntestinal bacteria promote -- and prevent! -- inflammatory bowel disease
Scientists search for drug candidates in some very unlikely places. Not only do they churn out synthetic compounds in industrial-scale laboratories, but they also scour coral reefs and scrape tree bark in the hope of…
29 May 2008
NewsCholesterol modulates sorting of CEA -- implications for inflammatory bowel disease
In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface.…